Newsletter
The Aducanumab Aftermath: The Payer

Archive-Tradeoffs

The Aducanumab Aftermath: The Payer

A controversial new $56,000 Alzheimer’s drug could wreak financial havoc on insurers, seniors and taxpayers.This episode is part of a special weeklong series examining the potentially sweeping consequences this drug,…
June 24, 2021

The Aducanumab Aftermath: The Payer

A controversial new $56,000 Alzheimer’s drug could wreak financial havoc on insurers, seniors and taxpayers.

This episode is part of a special weeklong series examining the potentially sweeping consequences this drug, known as aducanumab, could have on millions of patients’ lives and billions of dollars in health care spending.

Guest:

Mark Miller, PhD, Executive Vice President for Health Care, Arnold Ventures

Explore the full series and additional resources: https://tradeoffs.org/aducanumab

Read a transcript of this episode: https://tradeoffs.org/2021/06/24/the-aducanumab-aftermath-the-payer/

Sign up for our weekly newsletter to see what research health policy experts are reading right now, plus recommendations from our staff: bit.ly/tradeoffsnewsletter

Support this type of journalism today, with a gift: https://tradeoffs.org/donate

Follow us on Twitter: https://twitter.com/tradeoffspod


See acast.com/privacy for privacy and opt-out information.

You may also like

Top Health Podcasts. Delivered to Your Inbox and Eardrums.

Join Our Newsletter

We gratefully acknowledge the many organizations that have generously supported our podcasts and platform.

Network Sponsors and Advertisers

Event and Media Partners

Buffer LinkedIn WhatsApp